Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Assets (2016 - 2025)

Ascendis Pharma A's Current Assets history spans 8 years, with the latest figure at $756.1 million for Q4 2023.

  • For Q4 2023, Current Assets fell 19.75% year-over-year to $756.1 million; the TTM value through Dec 2023 reached $756.1 million, down 19.75%, while the annual FY2023 figure was $760.1 million, 21.9% down from the prior year.
  • Current Assets for Q4 2023 was $756.1 million at Ascendis Pharma A, down from $942.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $942.2 million in Q4 2022 and bottomed at $676.5 million in Q4 2019.
  • The 5-year median for Current Assets is $882.5 million (2020), against an average of $835.8 million.
  • The largest annual shift saw Current Assets soared 102.35% in 2019 before it dropped 19.75% in 2023.
  • A 5-year view of Current Assets shows it stood at $676.5 million in 2019, then soared by 30.45% to $882.5 million in 2020, then grew by 4.47% to $921.9 million in 2021, then increased by 2.2% to $942.2 million in 2022, then decreased by 19.75% to $756.1 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Current Assets are $756.1 million (Q4 2023), $942.2 million (Q4 2022), and $921.9 million (Q4 2021).